Current eye research · 2026
Efficacy of Bakuchiol in a Rat Model of Chemical Eye Injury.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bilmez Tan Rumeysa, Tekin Serek, Akman İlik Zehra, Batur Muhammed, Seven Erbil, Tan Uygun Meltem
Аннотация
PURPOSE: To evaluate the therapeutic effects of bakuchiol on clinical and histopathological outcomes in a rat model of corneal alkali burn.
METHODS: Corneal alkali burns were induced in the right eyes of 35 male Wistar rats, which were randomized into five groups: control, carbomer, steroid, 0.14 mg/g bakuchiol, and 0.28 mg/g bakuchiol. Examinations were performed under stereomicroscopy with intraperitoneal ketamine anesthesia on days 0, 3, 7, and 14 to assess corneal epithelial defects and opacity; on day 14, corneal neovascularization was additionally evaluated. After the final examination, the eyes were enucleated, and the corneas were processed for hematoxylin-eosin and immunohistochemical staining. Epithelial necrosis, inflammatory cell density, corneal hemorrhage, stromal edema, and staining intensity for VEGF and TNF-α were semi-quantitatively scored.
RESULTS: Bakuchiol treatment, particularly at 0.28 mg/g, significantly reduced corneal opacity, neovascularization, hemorrhage, and stromal edema compared with the steroid-treated group.
CONCLUSIONS: Bakuchiol demonstrated promising anti-inflammatory and anti-angiogenic effects and may represent a potential adjunctive treatment for corneal chemical injuries.
METHODS: Corneal alkali burns were induced in the right eyes of 35 male Wistar rats, which were randomized into five groups: control, carbomer, steroid, 0.14 mg/g bakuchiol, and 0.28 mg/g bakuchiol. Examinations were performed under stereomicroscopy with intraperitoneal ketamine anesthesia on days 0, 3, 7, and 14 to assess corneal epithelial defects and opacity; on day 14, corneal neovascularization was additionally evaluated. After the final examination, the eyes were enucleated, and the corneas were processed for hematoxylin-eosin and immunohistochemical staining. Epithelial necrosis, inflammatory cell density, corneal hemorrhage, stromal edema, and staining intensity for VEGF and TNF-α were semi-quantitatively scored.
RESULTS: Bakuchiol treatment, particularly at 0.28 mg/g, significantly reduced corneal opacity, neovascularization, hemorrhage, and stromal edema compared with the steroid-treated group.
CONCLUSIONS: Bakuchiol demonstrated promising anti-inflammatory and anti-angiogenic effects and may represent a potential adjunctive treatment for corneal chemical injuries.